Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | BRS3 | P32247 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2524469 | 0.99 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DBRS3 | |
| SCHEMBL1553374 | 0.89 | PLA2G2A (0.47) | PDE4APDE4BPDE4CPDE4DBRS3 | |
| SCHEMBL2524466 | 0.89 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DBRS3 | |
| SCHEMBL1553610 | 0.88 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL8575070 | 0.87 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2524512 | 0.85 | HSD17B10 (0.42) | PDE4APDE4BPDE4CPDE4DBRS3 | |
| SCHEMBL1552751 | 0.83 | SMN1; SMN2 (0.50) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL1554340 | 0.83 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DBRS3 | |
| Hydrochloric Acid SCHEMBL8568583 | 0.82 | SMN1; SMN2 (0.49) | PDE4APDE4BPDE4CPDE4DPDE10A | |
| SCHEMBL1553391 | 0.82 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DBRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | claimed |
| EP-2125753-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | claimed |
| WO-2008082003-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | WO | claimed |
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-0934307-B1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-2223920-A2 | Substituted azabicyclic compounds | Aventis Pharma Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
| EP-2125753-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008082003-A1 | FUSED HETEROCYCLIC COMPOUNDS HAVING CRF ANTAGONISTIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20050038069-A1 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | PDE4A 76/4885PDE4B 85/4885PDE4C 115/4885 |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | PDE4A 2118/4885PDE4B 2609/4885PDE4C 3089/4885 |
| US-20050038069-A1 | Substituted azabicyclic compounds | NR2C2, NR3C1, NR3C2 | PDE4A 3861/4885PDE4B 3722/4885PDE4C 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.